Marcaine 0,5% Adréenaline (Epinephrine, Bupivacaine Hydrochloride, Anhydrous)

Bupivacaine blocks voltage‑gated sodium channels on nerve membranes, preventing the initiation and propagation of action potentials. This inhibition stops nerve signal transmission, resulting in loss of sensation. The added epinephrine causes local vasoconstriction, slowing systemic absorption and extending the anesthetic duration.

The dose of Marcaine 0,5% Adréenaline is determined by the prescribing clinician based on the type of procedure, patient age, weight, and overall health. Only qualified healthcare professionals should calculate and administer the appropriate volume to ensure safety and efficacy.

Safety data for Marcaine 0,5% Adréenaline in pregnancy and lactation are limited. It should be used only when the potential benefit justifies any potential risk to the fetus or infant, and decisions should be made in consultation with a obstetric or pediatric specialist.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and required import documentation.

Marcaine (bupivacaine with epinephrine) offers a longer duration of action than shorter‑acting agents such as lidocaine. The epinephrine component reduces systemic uptake, prolonging effect and decreasing bleeding. However, its potency requires careful dosing and monitoring, especially in patients with cardiovascular concerns.

Marcaine 0,5% Adréenaline should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Before use, allow the solution to reach room temperature if required, and inspect for particulate matter or discoloration.

The product is supplied as an injectable solution for epidural or infiltration administration. A qualified clinician injects the appropriate volume directly into the target tissue or epidural space using aseptic technique, often under imaging guidance for precise placement.

Serious risks include cardiovascular toxicity such as severe hypertension, arrhythmias, or cardiac arrest, and central nervous system toxicity leading to seizures or loss of consciousness. Rarely, anaphylactic reactions or methemoglobinemia may occur, requiring immediate medical intervention.

Patients with known hypersensitivity to bupivacaine, epinephrine, or any component of the formulation should avoid this product. It is also contraindicated in individuals with certain cardiac conditions, uncontrolled hypertension, or those taking non‑selective alpha‑blockers without careful monitoring.